This work was supported by grant from the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; 04/15526-9, 08/58491-1, and 11/51697-6). H.S.N. and M.J.M. were recipients of fellowships from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; 301306/2010-9, 302006/2009-5, and 474708/06-3). J.A.P. and C.Y.M. were recipients of CNPq and FAPESP fellowships (142935/2011-5 and 08/54775-5).
Understanding the beneficial effects of doxycycline on the dystrophic phenotype of the mdx mouse
Article first published online: 17 JUN 2014
© 2014 Wiley Periodicals, Inc.
Muscle & Nerve
Volume 50, Issue 2, pages 283–286, August 2014
How to Cite
Pereira, J. A., Matsumura, C. Y., Minatel, E., Marques, M. J. and Santo Neto, H. (2014), Understanding the beneficial effects of doxycycline on the dystrophic phenotype of the mdx mouse. Muscle Nerve, 50: 283–286. doi: 10.1002/mus.24177
- Issue published online: 21 JUL 2014
- Article first published online: 17 JUN 2014
- Accepted manuscript online: 16 JAN 2014 10:56AM EST
- Manuscript Accepted: 14 JAN 2014
- calsequestrin 1;
Introduction: The purpose of this study was to better understand the beneficial effects of doxycycline on the dystrophic muscles of the mdx mouse. Methods: Doxycycline (DOX) was administered for 36 days, starting on postnatal day 0, via drinking water. Untreated mdx mice received plain water for the same period and served as a control group. Results: DOX decreased the levels of metalloproteinase-9 and tumor necrosis factor-alpha in the biceps brachii and diaphragm of the mdx mice. It also reduced the total amount of calcium in the muscles studied, concomitant with an increase in the levels of calsequestrin 1. Conclusions: The results show that DOX can affect factors that are important in dystrophic pathogenesis and highlight its potential as a readily accessible therapy in clinical trials for treatment of Duchenne muscular dystrophy. Muscle Nerve 50:283–286, 2014